Innopran XL: Advanced Beta-Blocker Therapy for Hypertension Control
Innopran XL
| Product dosage: 40mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.90 | $57.00 (0%) | 🛒 Add to cart |
| 60 | $1.35 | $114.00 $81.00 (29%) | 🛒 Add to cart |
| 90 | $1.17 | $171.00 $105.00 (39%) | 🛒 Add to cart |
| 120 | $1.07 | $228.00 $129.00 (43%) | 🛒 Add to cart |
| 180 | $0.98 | $342.00 $177.00 (48%) | 🛒 Add to cart |
| 270 | $0.92 | $513.00 $249.00 (51%) | 🛒 Add to cart |
| 360 |
$0.89
Best per pill
|
$684.00 $321.00 (53%) | 🛒 Add to cart |
| Product dosage: 80mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.03 | $61.00 (0%) | 🛒 Add to cart |
| 60 | $1.43 | $122.00 $86.00 (30%) | 🛒 Add to cart |
| 90 | $1.22 | $183.00 $110.00 (40%) | 🛒 Add to cart |
| 120 | $1.12 | $244.00 $134.00 (45%) | 🛒 Add to cart |
| 180 | $1.02 | $366.00 $184.00 (50%) | 🛒 Add to cart |
| 270 | $0.95 | $549.00 $257.00 (53%) | 🛒 Add to cart |
| 360 |
$0.91
Best per pill
|
$732.00 $328.00 (55%) | 🛒 Add to cart |
Similar products
Innopran XL (propranolol hydrochloride) extended-release capsules represent a cornerstone in modern cardiovascular pharmacotherapy, offering precise 24-hour blood pressure management through advanced controlled-release technology. As a nonselective beta-adrenergic blocking agent, it provides cardioselective action that modulates sympathetic nervous system activity, reducing cardiac output and peripheral vascular resistance. This formulation is particularly engineered for once-daily dosing convenience while maintaining stable plasma concentrations, making it an optimal choice for long-term hypertension management. Clinical evidence demonstrates its efficacy in reducing cardiovascular morbidity while maintaining favorable tolerability profiles in appropriately selected patient populations.
Features
- Contains propranolol hydrochloride as active pharmaceutical ingredient
- Extended-release formulation using osmotic pump technology
- Available in 80mg, 120mg, and 160mg strength capsules
- pH-independent release mechanism for consistent absorption
- Once-daily dosing regimen with 24-hour therapeutic coverage
- Bioequivalent to immediate-release formulations at steady state
- Manufactured under current Good Manufacturing Practices (cGMP)
- Stability maintained across various environmental conditions
Benefits
- Provides smooth 24-hour blood pressure control without peak-trough fluctuations
- Reduces cardiovascular event risk through consistent hypertension management
- Minimizes sympathetic overactivity-related symptoms such as palpitations and anxiety
- Offers convenient once-daily dosing that improves medication adherence
- Demonstrates proven efficacy in diverse patient populations including geriatric patients
- Maintains quality of life by reducing hypertension-related symptoms and complications
Common use
Innopran XL is primarily indicated for the management of hypertension, either as monotherapy or in combination with other antihypertensive agents. It is particularly valuable in patients with concomitant conditions such as migraine prophylaxis, essential tremor, or situational anxiety where beta-blockade provides additional therapeutic benefits. The extended-release formulation makes it especially suitable for patients requiring stable 24-hour beta-blockade, including those with labile hypertension or circadian blood pressure variations. Clinical guidelines recommend its use in stage 1 and stage 2 hypertension, often as first-line therapy in younger patients or those with hyperdynamic circulation.
Dosage and direction
The recommended initial dosage for hypertension management is 80mg once daily, preferably taken in the morning. Dosage may be increased to 120mg or 160mg once daily based on therapeutic response and tolerability, with increments typically made at 2-4 week intervals. Maximum recommended daily dose is 640mg, though most patients achieve adequate control at 160-320mg daily. Administration should occur at the same time each day, with or without food, but consistency in administration relative to meals is recommended. Capsules must be swallowed whole and not crushed, chewed, or divided. Dose adjustments are necessary in hepatic impairment, with recommended reduction of approximately 50% in patients with significant liver dysfunction.
Precautions
Patients should undergo comprehensive cardiovascular assessment before initiation, including evaluation of cardiac function, heart rate, and conduction abnormalities. Hepatic and renal function should be assessed periodically during therapy. Abrupt discontinuation may precipitate rebound hypertension, angina exacerbation, or myocardial infarction; gradual tapering over 1-2 weeks is mandatory. Caution is advised in patients with compensated heart failure, diabetes mellitus (may mask hypoglycemic symptoms), thyrotoxicosis, or peripheral vascular disease. Regular monitoring of blood pressure, heart rate, and clinical status is essential throughout treatment. Patients should be advised about potential fatigue, dizziness, or cold extremities, particularly during dose titration.
Contraindications
Innopran XL is contraindicated in patients with cardiogenic shock, sinus bradycardia, greater than first-degree heart block, heart failure with inadequate compensation, bronchial asthma, or severe chronic obstructive pulmonary disease. Additional contraindications include hypersensitivity to propranolol or any capsule components, untreated pheochromocytoma, and metabolic acidosis. The medication is not recommended during pregnancy unless clearly needed, and should be used with extreme caution in nursing mothers due to secretion in breast milk.
Possible side effect
Common adverse reactions (≥5% incidence) include fatigue, dizziness, bradycardia, cold extremities, and gastrointestinal disturbances. Less frequent effects (1-5%) may include sleep disturbances, depression, vivid dreams, bronchospasm in susceptible individuals, and erectile dysfunction. Rare but serious side effects (<1%) include heart failure exacerbation, conduction abnormalities, severe hypotension, bronchospasm requiring intervention, and exacerbation of psoriasis. Most side effects are dose-dependent and often diminish with continued therapy or dose adjustment.
Drug interaction
Significant interactions occur with calcium channel blockers (additive bradycardia and hypotension), antiarrhythmics (prolonged conduction), insulin and oral hypoglycemics (masked hypoglycemia), and sympathomimetics (reduced efficacy). Concurrent use with MAO inhibitors requires extreme caution due to hypertensive crisis risk. CYP2D6 and CYP1A2 inhibitors may increase propranolol concentrations, while inducers may reduce efficacy. Nonsteroidal anti-inflammatory drugs may attenuate antihypertensive effects. Digitalis glycosides may produce additive bradycardia. Close monitoring is essential when initiating or discontinuing concomitant medications.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If remembered near the time of the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Doubling of doses is not recommended due to potential excessive beta-blockade. Patients should be educated about maintaining consistent dosing intervals and establishing routines to minimize missed doses, as irregular administration may compromise blood pressure control.
Overdose
Manifestations include severe bradycardia, hypotension, heart failure, bronchospasm, hypoglycemia, and seizures. Management involves gastric lavage if presentation is early, followed by activated charcoal. Specific treatment includes atropine for bradycardia, vasopressors for hypotension, glucagon for myocardial depression, and bronchodilators for bronchospasm. Cardiac pacing may be necessary for refractory bradycardia. Hemodialysis is not effective due to high protein binding. Intensive care monitoring is essential until cardiovascular stability is achieved.
Storage
Store at controlled room temperature (20-25°C/68-77°F) with excursions permitted between 15-30°C (59-86°F). Protect from moisture and excessive heat. Keep in original container with tight closure. Do not transfer to other containers. Keep out of reach of children and pets. Discard any medication that appears discolored, damaged, or beyond the expiration date. Do not flush medications; dispose through proper medication take-back programs.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual patient responses may vary. Healthcare professionals should exercise clinical judgment when prescribing, considering individual patient characteristics and concurrent medications. Full prescribing information should be consulted before initiation. Patients should not adjust dosage or discontinue medication without medical supervision.
Reviews
Clinical studies demonstrate consistent blood pressure reduction with 70-80% of patients achieving target BP goals. Long-term extension studies show maintained efficacy over 12-24 months with stable safety profiles. Patient satisfaction surveys indicate high adherence rates due to once-daily dosing convenience. Real-world evidence supports effectiveness in diverse populations, though individual responses vary based on pharmacogenetic factors and comorbidities.